3 results
Frequency and clinical characteristics of nitrous oxide use disorder among French health professions students
- A. Dervaux, A. Szusterman, B. Angerville, L. Blecha, A. Benyamina, M. Naassila
-
- Journal:
- European Psychiatry / Volume 66 / Issue S1 / March 2023
- Published online by Cambridge University Press:
- 19 July 2023, p. S137
-
- Article
-
- You have access Access
- Open access
- Export citation
-
Introduction
Nitrous oxide recreational use and abuse has significantly increased in recent years among youth. To our knowledge, no previous study investigated the frequency and characteristics of N2O use disorder.
ObjectivesTo assess the frequency and the socio-demographic and clinical characteristics of nitrous oxide use disorder in a sample of health professions students.
MethodsAn online survey was distributed to health professions students at Paris-Cité University, Paris-Sorbonne University, Paris-Saclay University, Lille University and Picardy University, France. The following data were collected: age, gender, frequency of nitrous oxid use, DSM-5 criteria for nitrous oxide use disorder, frequency (day/week/month/year/lifetime) of tobacco, alcohol, cannabis, cocaine, amphetamines, and hallucinogens use, Alcohol Use Disorders Identification Test scores (AUDIT), the Fagerström Tobacco Dependence Test scores, the Cannabis Abuse Screening Test scores, lifetime psychiatric or sleep disorders.
Results2067 participants (mean age 21.7±2.6 years, 75% female) completed the survey from September 2021 to May 2022. Among them, 38% (n=790) reported nitrous oxide lifetime use. Seven per cent of the subjects (n=137) fulfilled DSM-5 criteria for current nitrous oxide use disorder (114 mild use disorder, 16 moderate use disorder, 7 severe use disorder). In the group of patients with nitrous oxide use disorder, there were correlations between nitrous oxide use disorder and daily alcohol use (Chi2=24.2, p<0.0001), daily tobacco use (Chi2=25.3, p<0.0001), AUDIT scores >12 (Chi2=7.9, p<0.0001), lifetime depressive disorders (Chi2 =13.6, p=0.0001), anxiety disorders (Chi2 =13.2, p=0.02), or sleep disorders (Chi2 =14.4, p=0.006), compared to the group of subjects without nitrous oxide use or the group of subjects without nitrous oxide use disorders.
ConclusionsNitrous oxide use and nitrous oxide use disorder were common among the health professions students included in the present study and correlated with daily alcohol or tobacco use.
Disclosure of InterestNone Declared
Alcohol related cognitive impairments in schizophrenia patients : A case-control study
- B. Angerville, N. Vaucher, F. Gierski, F. Benzerouk, S. Walesa, J. Seree, M.-C. Bralet, A. Benyamina, M. Naassila, A. Dervaux
-
- Journal:
- European Psychiatry / Volume 66 / Issue S1 / March 2023
- Published online by Cambridge University Press:
- 19 July 2023, p. S335
-
- Article
-
- You have access Access
- Open access
- Export citation
-
Introduction
Cognitive impairment is a well-recognized key feature of schizophrenia. However, these cognitive impairments may be worsened by alcohol consumption. Up to 80% of patients with alcohol use disorders (AUD) display cognitive impairments. Screening for those impairments with a full neuropsychological assessment may be difficult. The Brief Evaluation Alcohol-Related Neuropsychological Impairments (BEARNI) is a specific tool for screening those impairments easy to implement in in clinical practice (Ritz et al. Alcoholism: Clinical and Experimental Research 2015; 39, 2249-60). To our knowledge, no previous studies have assessed the alcohol-related cognitive impairments using the BEARNI test in schizophrenia patients.
ObjectivesThe objective of the study was to compare BEARNI mean scores between a group of schizophrenia patients with alcohol use disorders and a group of schizophrenia patients without alcohol use disorder.
Methods39 patients with schizophrenia and AUD (SCZ/AUD +) (82% males, mean age 44.9 ± 11.0 years-old) and 49 patients with schizophrenia without AUD (SCZ/AUD-) (65% males, mean age 42.6 ± 11.4 years-old) consecutively included in the study, were assessed using the BEARNI test. All patients met DSM-5 criteria for schizophrenia and AUD. Demographic and clinical variables were also collected, using the Alcohol Use Disorders Identification Test (AUDIT) and the Positive and Negative Syndrome Scale (PANSS). The primary endpoint of the study was the difference in BEARNI cognitive mean scores between the SCZ/AUD+ and SCZ/AUD- groups.
ResultsThere was no difference between the two groups regarding demographic variables or PANSS mean scores (59.1 ± 12.8 vs 58.1 ± 14.0; t=-0.3; p=0.7). The AUDIT mean score was higher in the group of patients SCZ/AUD+ (20.6 ± 7.8 vs 1.6 ± 1.5; t=-14.7; p<0.0001). Total BEARNI and cognitive BEARNI mean scores were significantly lower in the group of patients SCZ/AUD+ compared to the group of patients SCZ/AUD- (10.6 ± 4.8 vs 12.6 ± 5.2; t=1.8, p=0.03 and 8.1 ± 3.9 vs 9.8 ± 3.6 t=2.0, p=0.04, respectively). The mean subscores of delayed verbal memory, alphabetical ordination, and alternating verbal fluency subtests were also significantly lower in the group of patients SCZ/+ group (respectively 1,0 ± 0.9 vs 1.6 ± 1.2, t= 2.5, p=0.01; 2,1 ± 1.2 vs 2.5 ± 1.1, t= 1.6, p=0.04; 3.3 ±1.5 vs 3.8 ± 1.5, t= 1.8, p=0.03).
ConclusionsThe present study found cognitive impairments using BEARNI test in schizophrenia patients with AUD compared to their counterparts without AUD. Screening alcohol related cognitive impairments using BEARNI could be easier in patients in schizophrenia patients with AUD than usual neurocognitive assessments
Disclosure of InterestNone Declared
Alcohol related cognitive impairments in patients with and without cirrhosis
- B. Angerville, M.-A. Jurdana, R. Sarba, É. Nguyen-Khac, M. Naassila, A. Dervaux
-
- Journal:
- European Psychiatry / Volume 66 / Issue S1 / March 2023
- Published online by Cambridge University Press:
- 19 July 2023, p. S140
-
- Article
-
- You have access Access
- Open access
- Export citation
-
Introduction
Up to 80 % of patients with alcohol use disorders (AUD) display cognitive impairments. Some studies suggested that cognitive functions could be worsened by hepatic damage, particularly cirrhosis. Cirrhosis is widespread in patients with AUD, indeed one third of them develop cirrhosis during their lifetime (Zhang et al. Alcohol Clin Exp Res. 2022). Currently, patients treated for cirrhosis do not benefit from a systematic assessment of alcohol related cognitive impairments. The Brief Screening Tool for Alcohol-Related Neuropsychological Impairments (BEARNI) is a specific tool developed to screening for those impairments.
ObjectivesThe primary objective of this study was to compare BEARNI mean scores in a group of AUD patients with (AUD/C+) or without cirrhosis (AUD/C-).
MethodsWe conducted a prospective, monocentric study at the Amiens University Hospital. Subjects were consecutively recruited from the hepato-gastroenterology department of Amiens University hospital and from the local substance abuse treatment department. All patients were assessed using BEARNI test, demographical (age, gender, number of years of scholarship), and clinical variables, using Child-Pugh scores and Alcohol use disorders identification test (AUDIT). The BEARNI mean score in the AUD/C+ group was compared to the mean score in the AUD/C- group using an Analysis of covariance (ANCOVA) with age and educational level as covariate. Between group comparisons were performed using post hoc analysis with Tukey HSD test.
Results107 patients (75 AUD/C+, 32 AUD/C-) were included in this study. AUD/C- patients were significantly younger than AUD/C+ patients (respectively, 45.5 ± 6.8 vs 59.3 ± 9.3; p<0.0001). There were no differences regarding gender and years of scholarship. Child-Pugh mean scores were 6.9 ± 2.4 in the AUD/C+ group. AUDIT mean scores were significantly lower in the group of patients with AUD and cirrhosis than in the group of patients with AUD without cirrhosis. After adjusting on age and educational level, we found that mean BEARNI total and cognitive scores in the group of patients with AUD and cirrhosis were significantly lower than in the group of patients with AUD without cirrhosis (respectively, 13.8 ± 0.7 vs 7.8± 0.4 F=46.8; p<0.0001 and 10.6 ± 0.6 vs 6.9± 0.3; F=30.1; p<0.0001). The mean subscores of delayed verbal memory, alphabetical ordination, alternating verbal fluency and ataxia subtests were also significantly lower in the group of group of patients AUD/C + (respectively, 1.8 ± 0.1 vs 2.8 ± 0.2, F= 13.9, p<0.0001; 1.8 ± 0.1 vs 2.6 ± 0.2, F= 10.6, p<0.0001; 2.4 ± 0.1 vs 3.6 ± 0.2, F= 13.4, p<0.0001; 0.9 ± 0.2 vs 3.1 ± 0.2, F= 30.6, p<0.0001).
ConclusionsIn the present study, the patients with AUD and cirrhosis had more cognitive impairments than their counterparts without cirrhosis. Longitudinal studies are needed to investigate how cirrhosis can influence cognitive impairments.
Disclosure of InterestNone Declared